SITC Announces 2023 Class of Fellows to the Academy of Immuno-Oncology
The Society for Immunotherapy of Cancer (SITC) announces the 2023 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2023 class will be inducted at a private event during SITC's 38th Annual Meeting & Pre-Conference Programs, taking place November 1–5, 2023 in... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 30, 2023 Category: Pharmaceuticals Tags: TDS FVT Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
Basel, 23 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators. We are continuing the study until the final analysis for overall survival. All other stud...
Source: Roche Media News - August 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
Basel, 23 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators. We are continuing the study until the final analysis for overall survival. All other stud...
Source: Roche Investor Update - August 23, 2023 Category: Pharmaceuticals Source Type: news
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 -- The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors (ICIs), according to a study published in the August... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2023 Category: Pharmaceuticals Source Type: news
Tarlatamab: The Promising Immunotherapy on Its Way Tarlatamab: The Promising Immunotherapy on Its Way
Tarlatamab shows promise as a potential targeted treatment option for small cell lung cancer, but further research is warranted.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 21, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
New immunotherapy drug can DESTROY cancers in the lower part of the bowel - removing the need for an operation
Durvalumab can destroy cancers in the lower part of the bowel - removing the need for an operation. (Source: the Mail online | Health)
Source: the Mail online | Health - August 19, 2023 Category: Consumer Health News Source Type: news
Immunotherapy drug combo helps extend lives of people with metastatic melanoma
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to widely used immunotherapy drugs called PD-1 inhibitors.In clinical trials, the investigators found that the combination therapy could extend the amount of time patients live without their cancer worsening, known as progression-free survival, and that it helps overcome their resistance to prior immunotherapies — which would allow more people to benefit from the treatment.The study evaluated the use of the imm...
Source: UCLA Newsroom: Health Sciences - August 18, 2023 Category: Universities & Medical Training Source Type: news
Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships
In its mission to make "cure" a reality for cancer patients everywhere, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of the 2023 Fellowships. MILWAUKEE, Aug. 16, 2023 /PRNewswire-PRWeb/ -- In its mission to make "cure" a reality for... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 16, 2023 Category: Pharmaceuticals Tags: AWD NPT Source Type: news
Study shows promise of immunotherapy treatment for penile cancer
Yale researchers finds that the use of immune checkpoint inhibitors could expand limited treatment options for some patients with a rare form of penile cancer. (Source: Yale Science and Health News)
Source: Yale Science and Health News - August 15, 2023 Category: Universities & Medical Training Source Type: news
Cancer-infecting virus & #039;warms up & #039; cold tumors and improves immunotherapy
Equipping cancer-infecting, or oncolytic, viruses with tumor-inhibiting genetic cargo stimulates the immune system and helps immunotherapy to shrink or completely clear aggressive tumors in mice, according to a new study in the Journal of Experimental Medicine led by University of Pittsburgh and UPMC researchers. The results pave the way for clinical trials combining oncolytic viruses with immunotherapy. (Source: World Pharma News)
Source: World Pharma News - August 15, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Immune-Based Cancer Drugs Offer Hope Against Penile Cancers
TUESDAY, Aug. 15, 2023 -- Men who have a rare cancer of the penis may have a new treatment option, according to researchers who found promise in immunotherapy.
This new study focused on cancer that was locally advanced or had spread... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 15, 2023 Category: General Medicine Source Type: news
Peanut Oral Immunotherapy Effective for Children Under 12 Months
MONDAY, Aug. 14, 2023 -- Peanut oral immunotherapy (OIT) can induce desensitization to peanuts in children younger than 12 months of age, according to research published online July 13 in the Journal of Allergy and Clinical Immunology: In... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 14, 2023 Category: Pharmaceuticals Source Type: news
Hope for blood cancer patients after immunotherapy drug trials show 'groundbreaking results'
The Christie Foundation Trust in Manchester is running around 30 clinical trials for a set of drugs that are so cutting-edge that they don't yet have names (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2023 Category: Consumer Health News Source Type: news
